RCM
NVAX icon

Rotella Capital Management’s Novavax NVAX Stock Holding History

Rotella Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-693
Closed -$64K – 374
2014
Q2 		$64K Buy
+693
New +$60.9K 0.05% 288
2013
Q3 		– Sell
-500
Closed -$21K – 145
2013
Q2 		$21K Buy
+500
New +$21.7K 0.07% 131

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Rotella Capital Management's NVAX Position: Q3 2014 in Review

Rotella Capital Management sold out of Novavax (NVAX) in Q3 2014, closing a stake of 693 shares — an estimated $64K sold.

Rotella Capital Management first reported a position in NVAX in Q2 2013 and held it in 2 quarters. The position peaked at $64K in Q2 2014. 143 funds tracked by Wall St. Rank hold NVAX as of Q3 2014.

  • Rotella Capital Management reported no remaining Novavax position as of Q3 2014 after selling out during the quarter.
  • Rotella Capital Management sold 693 Novavax shares in Q3 2014, an estimated $64K.
  • Rotella Capital Management first reported a position in Novavax in Q2 2013 and held it in 2 quarters.
  • Rotella Capital Management's Novavax position peaked at $64K in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Novavax as of Q3 2014.

Based on Rotella Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.